Samsung Electronics' medical device subsidiary Samsung Medison announced on the 21st that its revenue for the first half of this year increased by 14% compared to the same period last year, surpassing 300 billion won.
The company noted that "as a result of winning public tenders in Europe and expanding its entry into large hospitals in the United States," and added, "if the current trend continues, annual revenue this year is expected to reach an all-time high."
Samsung Medison supplies ultrasound diagnostic equipment to more than 100 countries and exports account for over 90% of its revenue. Its revenue has grown from 308.4 billion won in 2020 to 397.3 billion won in 2021, 485.1 billion won in 2022, 517.4 billion won in 2023, and 571.2 billion won in 2024.
Celebrating its 40th anniversary this year, Samsung Medison plans to accelerate its leap as a leader in the ultrasound diagnostic equipment industry based on comprehensive investments for future growth, including enhancing global sales capacity, securing next-generation technologies such as artificial intelligence (AI), and expanding portfolio and production capabilities. The company is currently expanding its Hongcheon factory, which has introduced automated facilities and smart processes, and plans to increase its annual production by more than 50% by 2026, aiming to double its current production by 2030 when the expansion of its second factory is completed.
Yu Gyu-tae, CEO of Samsung Medison, stated, "Samsung Medison will continue to develop next-generation medical technologies to provide better diagnostic experiences for both medical staff and patients," and added, "By augmenting the trust built with global medical staff over the past 40 years with proactive investments, we will emerge as a leading global diagnostic corporations."